Research programme: antimalarials - AERES BiomedicalAlternative Names: ABC-120; Anti-malaria antibody - AERES Biomedical; Antimalarial humanised antibody -AERES Biomedical; Antimalarials research programme - AERES Biomedical
Latest Information Update: 10 Sep 2005
At a glance
- Originator AERES Biomedical
- Class Antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 10 Sep 2005 This programme is still in active development
- 10 Jul 2003 Preclinical trials in Malaria in United Kingdom (unspecified route)